Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Retained Earnings (2016 - 2026)

Lexaria Bioscience's Retained Earnings history spans 12 years, with the latest figure at -$55444.0 for Q1 2026.

  • On a quarterly basis, Retained Earnings rose 99.9% to -$55444.0 in Q1 2026 year-over-year; TTM through Feb 2026 was -$55444.0, a 99.9% increase, with the full-year FY2025 number at -$70335.0, up 99.86% from a year prior.
  • Retained Earnings hit -$55444.0 in Q1 2026 for Lexaria Bioscience, up from -$65.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for LEXX hit a ceiling of -$20626.0 in Q1 2024 and a floor of -$65.1 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$31.9 million across 5 years, with a median of -$40.0 million in 2022.
  • Biggest five-year swings in Retained Earnings: skyrocketed 99.95% in 2024 and later tumbled 282861.25% in 2025.
  • Tracing LEXX's Retained Earnings over 5 years: stood at -$40.9 million in 2022, then decreased by 14.9% to -$46.9 million in 2023, then surged by 99.95% to -$22991.0 in 2024, then tumbled by 282861.25% to -$65.1 million in 2025, then skyrocketed by 99.91% to -$55444.0 in 2026.
  • Business Quant data shows Retained Earnings for LEXX at -$55444.0 in Q1 2026, -$65.1 million in Q4 2025, and -$70335.0 in Q3 2025.